Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro

Narayana, Revu Vl; Jana, Pritikana; Tomar, Neha R.; Prabhu, Varsha; Nair, Rohini; Manukonda, Radhika; Kaliki, Swathi; Coupland, Sarah E.; Alexander, Jodi; Kalirai, Helen; Kondapi, Anand K.; Vemuganti, Geeta K.

doi:10.1167/iovs.62.14.13

Cited by 34 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 Lactoferrin nanoparticles (Lf-Nps) have been evaluate for cytotoxicity of etoposide, (topoisomerase inhibitor) and carboplatin in vitro, against the growth of retinoblastoma-Y79 cells. 41 Lactoferrin is an iron transporting glycoprotein (transferrin family) shown to improve target recognition in several studies. 42 The drug localization observed with lactoferrin nanoparticles is associated with expression of lactoferrin receptors in target cancer cells.…”

Section: Effective Treatment Approachmentioning

confidence: 99%

“…42 Narayana et al, confirmed significant intracellular drug uptake, and cytotoxicity profile, for carboplatin (CPT)-and etoposide (ETP)-loaded lactoferrin nanoparticles (Lf-Nps) in retinoblastoma Y79 cells. 41 Drug agents loaded in lactoferrin nanoparticles (Lf-Nps) doubled overall cellular uptake compared to carboplatin (CPT) or etoposide (ETP) alone. 41 Additionally, the cytotoxic effect increased up to 50% with carboplatin (CPT)-and etoposide (ETP)loaded lactoferrin nanoparticles(Lf-Nps) compared to controls.…”

Section: Effective Treatment Approachmentioning

confidence: 99%

“…41 Drug agents loaded in lactoferrin nanoparticles (Lf-Nps) doubled overall cellular uptake compared to carboplatin (CPT) or etoposide (ETP) alone. 41 Additionally, the cytotoxic effect increased up to 50% with carboplatin (CPT)-and etoposide (ETP)loaded lactoferrin nanoparticles(Lf-Nps) compared to controls. 41 Epithelial cell adhesion molecule (EpCAM) is a cell surface molecule which is overexpressed in retinoblastoma resulting in cell proliferation.…”

Section: Effective Treatment Approachmentioning

confidence: 99%

“…41 Additionally, the cytotoxic effect increased up to 50% with carboplatin (CPT)-and etoposide (ETP)loaded lactoferrin nanoparticles(Lf-Nps) compared to controls. 41 Epithelial cell adhesion molecule (EpCAM) is a cell surface molecule which is overexpressed in retinoblastoma resulting in cell proliferation. 43 Selectively inhibiting EpCAM on retinoblastoma is shown to deregulate genes controlling growth; thereby, reducing cell survival.…”

Section: Effective Treatment Approachmentioning

confidence: 99%

See 3 more Smart Citations

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

Patel

Conte

Luo

et al. 2022

MRAJ

View full text Add to dashboard Cite

Retinoblastoma is the most common type of eye cancer in infants and children. Probability of saving vision and survival depends upon two main factors: progression of the disease from unilateral to bilateral and severity of the disease. In order to effectively treat retinoblastoma and retain vision, it is crucial to focus treatment options on reducing toxicity and nonspecific targeting while enhancing drug delivery, cellular uptake, and accumulation of chemotherapeutic agents to their specific target sites. Rapid elimination from blood circulation is the greatest obstacle that conventional chemotherapeutic agents face on journey to their target sites. Target specific nanoparticles have proven to be a useful tool in efforts to overcome challenges typically encountered by targeting strategies. Development of nanoparticles loaded with chemotherapeutic agents can allow for more selective tumor targeting, extended drug circulation times, and reduced drug-associated toxicity. Nanoparticles can significantly improve the treatment efficacy in retinoblastoma. The purpose of this review is to discuss the important characteristics and differences of nano delivery systems used against cellular and in vivo models of retinoblastoma, particularly as they relate to the popular Y79 retinoblastoma cell line.

show abstract

Section: Effective Treatment Approachmentioning

confidence: 99%

Section: Effective Treatment Approachmentioning

confidence: 99%

Section: Effective Treatment Approachmentioning

confidence: 99%

Section: Effective Treatment Approachmentioning

confidence: 99%

See 2 more Smart Citations

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

Patel

Conte

Luo

et al. 2022

MRAJ

View full text Add to dashboard Cite

show abstract

“…[ 5 6 ] In our attempt to investigate the role of CSCs in Y79 cell line, we had demonstrated that FSC lo /SSC lo /CD133 lo subset has the properties of CSCs in vitro such as colony-forming ability, differentiation, chemoresistance, invasion, and stem cell-specific gene expression signature. [ 7 8 ] Translation of in vitro studies to in vivo model systems has become an integral part of functional tumor biology studies and clinically relevant model systems help in developing better treatment strategies. [ 9 ] Several genetic and xenograft animal models have been established to explore Rb tumorigenesis, metastasis, and targeted therapies.…”

mentioning

confidence: 99%

A short-term chick embryo in vivo xenograft model to study retinoblastoma cancer stem cells

Nair

Revu

Gali

et al. 2022

Indian Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

Purpose: Cancer stem cells (CSCs) reported in various tumors play a crucial role in tumorigenesis and metastasis of retinoblastoma (Rb). Following the efforts to reduce, replace, and refine the use of mammalian models, we aimed to establish a short-term xenograft for Rb to evaluate the CSC properties of CD133 - Rb Y79 cells, using the well-established chick embryo chorioallantoic membrane (CE-CAM) assay. Methods: Y79 cells were cultured, labeled with two different dyes (CM-Dil Y79 and enhanced green fluorescent protein (eGFP)) and sorted for CD133 - and CD133 + subsets. Two million cells from each of the labeled groups were transplanted onto the abraded CAM on embryonic day 7 (E7). On E14, the tumor nodule formation on CAM and spontaneous metastasis to the embryos were evaluated by confocal microscopy, in vivo imaging, and histology. Results: Y79 cells formed pink–white raised perivascular nodules with feeder vessels on the CAM with both the types of labeled CD133 - cells. CD133 - cells, when compared to CD133 + cells, demonstrated significantly larger tumor volume (40.45 ± 7.744 mm 3 vs 3.478 ± 0.69 mm 3 , P = 0.0014) and higher fluorescence intensity (CM-Dil: AUF = 6.37 × 10 7 ± 7.7 × 10 6 vs 1.08 × 10 7 ± 1.6 × 10 6 ; P < 0.0001; eGFP: AUF = 13.94 × 10 4 ± 2.54 × 10 4 vs AUF = 1.39 × 10 4 ± 0.4 × 10 4 ; P = 0.0003). The metastatic potential of CD133 - cells was also observed to be higher as noted by in vivo imaging and histopathology. Conclusion: This study highlights that CE-CAM is a feasible alternative nonmammalian model for evaluating tumorigenicity and metastatic potential of Y79 CSCs. Increased tumorigenicity and metastatic potential of CD133 - subset of tumor cells substantiate their CSC properties.

show abstract

Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer

Muj

Mukhopadhyay

Jana

et al. 2023

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro

Cited by 34 publications

References 43 publications

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

A short-term chick embryo in vivo xenograft model to study retinoblastoma cancer stem cells

Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer

Contact Info

Product

Resources

About